Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: heart disease

Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis

Carina Stanton  |  August 17, 2018

For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al….

Filed under:ConditionsVasculitis Tagged with:ActemraTakayasu arteritis (TAK)tocilizumab

From Dog Clickers to Scripts—Thoughts on Learning to Teach

Philip Seo, MD, MHS  |  August 16, 2018

You can purchase a dog clicker for about $3 on Amazon. If you don’t own a dog, this is not a useful piece of information. I don’t own a dog, and the first time I heard the phrase dog clicker, I thought—I think understandably—that it was some sort of remote control. If you don’t own…

Filed under:Career DevelopmentEducation & TrainingOpinionRheuminationsSpeak Out Rheum Tagged with:Preceptorshipteaching physicians

Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

Vaneet Kaur Sandhu, MD, & Kathleen Teves, MD  |  August 16, 2018

Antiphospholipid syndrome (APS) is an autoimmune clotting disorder that may present catastrophically with multiple thromboses over a short period of time. In this article, we examine the case of a woman with undiagnosed APS whose first symptoms presented during a long-haul flight. A review of the literature on thrombosis at high altitudes and during long…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Antiphospholipid Antibody Syndrome (APS)blood clotHughes Syndrome

2018 ACR/ARHP Annual Meeting Courses, Opening Lecture & Keynote

From the College  |  July 19, 2018

Join us in Chicago for the 2018 ACR/ARHP Annual Meeting on Oct. 19–24. Register now to save; advance registration rates end Oct. 3. High-Impact Learning Starts with Pre-Meeting Courses Pre-meeting courses offer attendees unique learning opportunities in specific topic areas. The pre-meeting courses will be held at McCormick Place Oct. 19–20. No matter your area…

Filed under:From the College Tagged with:2018 ACR/ARHP Annual Meeting

Improve Your Recognition & Treatment of Osteoporosis

Jason Liebowitz, MD, FACR  |  July 19, 2018

BALTIMORE—Rheumatologists may not think about osteoporosis on a daily basis, but they should, said Dr. Karl Insogna, the Ensign Professor of Medicine at Yale University School of Medicine and director of the Yale Bone Center in New Haven, Conn., in his recent lecture at the Maryland Society for the Rheumatic Diseases. With approximately 75 million…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:alendronatebisphosphonatesCorticosteroidsdenosumabOsteoporosisraloxifenerisedronateteriparatidezoledronic acid

Medical Tech-Tool Usage Is Surging

Susan Bernstein  |  July 19, 2018

Technology in medicine is no longer new or trendy. It’s pervasive. Rheumatologists may now assume a patient has searched online for information about his or her diagnosis or potential therapies. Both physicians and rheumatology health professionals should acknowledge their patients’ Internet surfing and find out what they’ve read, says Betsy Roth-Wojcicki, RN, MS, CPNP, an…

Filed under:AppsTechnologyTechnology Tagged with:Social Media

The Demise of the Inpatient Rheumatology Unit

Ruth Jessen Hickman, MD  |  July 19, 2018

Through much of the 20th century, dedicated rheumatic disease units were found in hospitals across the U.S. and countries around the world. In the latter part of the century, this began to change, with hospitals moving toward the consult model of care for rheumatic patients. This change reflects larger shifts in the medical world toward…

Filed under:Practice Support Tagged with:inpatientoutpatient

Case Report: Ehlers-Danlos Syndrome Mimicking Vasculitis

Case Report: Ehlers-Danlos Syndrome Mimicking Vasculitis

Catherine (Katie) Donnelly, MB, BCh, BAO, & Surabhi Khanna, MD  |  July 19, 2018

A 43-year-old man with a past medical history of type 2 diabetes mellitus, bilateral inguinal hernia repair as a child and prior cholecystectomy woke from sleep with sudden-onset periumbilical abdominal pain. He was admitted to another hospital, but required transfer to our surgical intensive care unit after a recurrent episode of severe abdominal pain, during…

Filed under:Vasculitis Tagged with:Ehlers-Danlosmimics

A Comprehensive Review of NSAID Cardiovascular Toxicity

A Comprehensive Review of NSAID Cardiovascular Toxicity

Deepan S. Dalal, MD, MPH, Maureen Dubreuil, MD, MS, & David T. Felson, MD, MPH  |  July 18, 2018

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

Filed under:Analgesics Tagged with:acetaminophencelecoxib (Elyxyb)diclofenacIbuprofennaproxenNSAIDsrofecoxib

Understanding & Treating Neonatal Lupus

Thomas R. Collins  |  June 21, 2018

CHICAGO—Neonatal lupus is a rare disorder, but its onset can be dramatic, and it can be fatal. Clinicians must be armed with information to manage it and help guide parents through difficult decisions, an expert said in April at the State-of-the-Art Clinical Symposium. Despite the name, neonatal lupus does not mean that either the mother…

Filed under:Systemic Lupus Erythematosus Tagged with:Neonatal lupus erythematosus

  • « Previous Page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • …
  • 81
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences